Virus-like particles as immunogens

Trends in Microbiology

Volumn 11, Issue 9, 2003, Pages 438-444

  Noad, Rob ^a   Roy, Polly ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM DERIVATIVE; ALUMINUM OXIDE; CANINE PARVOVIRUS VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ISCOM; JC VIRUS VACCINE; NORWALK VIRUS VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; PROTEIN VP2; PROTEIN VP3; PROTEIN VP5; PROTEIN VP7; QUIL A; RECOMBINANT PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE; VIRUS VECTOR; WART VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; BACULOVIRUS; BIRNAVIRIDAE; BUNYAVIRUS; CALICIVIRUS; CATTLE DISEASE; CIRCOVIRIDAE; CLINICAL TRIAL; DRUG EFFICACY; ESCHERICHIA COLI; FEVER; FLAVIVIRUS; GENE EXPRESSION SYSTEM; HEPADNAVIRIDAE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A; INJECTION SITE; INSECT CELL; JC VIRUS; MAMMAL CELL; NONHUMAN; NORWALK GASTROENTERITIS VIRUS; ORTHOMYXOVIRUS; PAIN; PAPILLOMA VIRUS; PARAMYXOVIRUS; PARVOVIRUS; PICORNAVIRUS; POLIOMYELITIS; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN TARGETING; REOVIRUS; RETROVIRUS; REVIEW; SHEEP DISEASE; SIDE EFFECT; VACCINATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIREMIA; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS PARTICLE; WART VIRUS; YEAST;

BIRNAVIRIDAE; BOS TAURUS; CALICIVIRIDAE; CANINE PARVOVIRUS; CIRCOVIRIDAE; ESCHERICHIA COLI; FLAVIVIRUS; HEPADNAVIRIDAE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN PAPILLOMAVIRUS TYPES; INFLUENZA VIRUS; INFLUENZAVIRUS A; INSECTA; JC VIRUS; MAMMALIA; NORWALK VIRUS; ORTHOBUNYAVIRUS; ORTHOMYXOVIRIDAE; OVIS ARIES; PAPILLOMAVIRUS; PARAMYXOVIRIDAE; PARVOVIRUS; PICORNAVIRIDAE; POLYOMAVIRUS; REOVIRUS SP.; UNIDENTIFIED BACULOVIRUS; UNIDENTIFIED RETROVIRUS; VACCINIA VIRUS;

EID: 0042825878     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(03)00208-7     Document Type: Review

References (78)

1. Smithburn K.C. Rift Valley fever: the neurotropic adaption of virus and experimental use of this modified virus as a vaccine. Br. J. Exp. Pathol. 30:1949;1-16.
2. Caplen H., et al. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66:1985;2271-2277.
3. Miyanohara A., et al. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J. Virol. 59:1986;176-180.
4. Delchambre M., et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J. 8:1989;2653-2660.
5. Gheysen D., et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell. 59:1989;103-112.
6. French T.J., et al. Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. J. Virol. 64:1990;5695-5700.
7. Schirmbeck R., et al. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology. 39:1996;111-119.
8. + cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses. 16:2000;273-282.
9. Murata K., et al. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl. Acad. Sci. U. S. A. 100:2003;6753-6758.
10. Rueda P., et al. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine. 19:2000;726-734.
11. Maranga L., et al. Production of core and virus-like particles with baculovirus infected insect cells. Adv. Biochem. Eng. Biotechnol. 74:2002;183-206.
12. McAleer W.J., et al. Human hepatitis B vaccine from recombinant yeast. Nature. 307:1984;178-180.
13. Stahl S.J., Murray K. Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proc. Natl. Acad. Sci. U. S. A. 86:1989;6283-6287.
14. Kratz P.A., et al. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl. Acad. Sci. U. S. A. 96:1999;1915-1920.
15. Zhou J., et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 185:1991;251-257.
16. Kirnbauer R., et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U. S. A. 89:1992;12180-12184.
17. Sasagawa T., et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology. 206:1995;126-135.
18. Dupuy C., et al. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J. Virol. 73:1999;9063-9071.
19. Zhang L.F., et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine. 18:2000;1051-1058.
20. Koutsky L.A., et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:2002;1645-1651.
21. Evans T.G., et al. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183:2001;1485-1493.
22. Harro C.D., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:2001;284-292.
23. Lopez de Turiso J.A., et al. Recombinant vaccine for canine parvovirus in dogs. J. Virol. 66:1992;2748-2753.
24. Martinez C., et al. Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine. 10:1992;684-690.
25. Maranga L., et al. Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl. Microbiol. Biotechnol. 59:2002;45-50.
26. Ball J.M., et al. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol. 72:1998;1345-1353.
27. Guerrero R.A., et al. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75:2001;9713-9722.
28. Ball J.M., et al. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology. 117:1999;40-48.
29. Goldmann C., et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J. Virol. 73:1999;4465-4469.
30. Brautigam S., et al. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology. 192:1993;512-524.
31. Kibenge F.S., et al. Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. Can. J. Vet. Res. 63:1999;49-55.
32. French T.J., Roy P. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J. Virol. 64:1990;1530-1536.
33. Roy P. Fields B.N. Orbiviruses and their Replication. 2000;Lippincott-Raven.
34. Belyaev A.S., Roy P. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Res. 21:1993;1219-1223.
35. Roy P., et al. Protective efficacy of virus-like particles for bluetongue disease. Vaccine. 10:1992;28-32.
36. Roy P., et al. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine. 12:1994;805-811.
37. Roy P., et al. Recombinant virus vaccine for bluetongue disease in sheep. J. Virol. 64:1990;1998-2003.
38. Sabara M., et al. Assembly of double-shelled rotaviruslike particles by simultaneous expression of recombinant VP6 and VP7 proteins. J. Virol. 65:1991;6994-6997.
39. Jiang B., et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine. 17:1999;1005-1013.
40. Madore H.P., et al. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine. 17:1999;2461-2471.
41. Betenbaugh M., et al. Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus. Virus Res. 38:1995;111-124.
42. Yamshchikov G.V., et al. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology. 214:1995;50-58.
43. Baumert T.F., et al. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J. Virol. 72:1998;3827-3836.
44. Latham T., Galarza J.M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 75:2001;6154-6165.
45. Yao Q., et al. Production and characterization of simian/human immunodeficiency virus-like particles. AIDS Res. Hum. Retroviruses. 16:2000;227-236.
46. Lechmann M., et al. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology. 34:2001;417-423.
47. Wagner R., et al. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology. 39:1996;93-103.
48. Yao Q., et al. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine. 20:2002;2537-2545.
49. Adams S.E., et al. The expression of hybrid HIV:Ty virus-like particles in yeast. Nature. 329:1987;68-70.
50. Beyer T., et al. Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation. Curr. Drug Targets Infect. Disord. 1:2001;287-302.
51. Sedlik C., et al. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 94:1997;7503-7508.
52. Lo-Man R., et al. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur. J. Immunol. 28:1998;1401-1407.
53. Goldmann C., et al. Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus. J. Virol. Methods. 90:2000;85-90.
54. Jiang X., et al. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66:1992;6527-6532.
55. Laurent S., et al. Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection. J. Virol. 68:1994;6794-6798.
56. Pletneva M.A., et al. Characterization of a recombinant human calicivirus capsid protein expressed in mammalian cells. Virus Res. 55:1998;129-141.
57. Hale A.D., et al. Expression and self-assembly of Grimsby virus: antigenic distinction from Norwalk and Mexico viruses. Clin. Diagn. Lab. Immunol. 6:1999;142-145.
58. Belliot G., et al. Characterization of capsid genes, expressed in the baculovirus system, of three new genetically distinct strains of Norwalk-like viruses. J. Clin. Microbiol. 39:2001;4288-4295.
59. Li T.C., et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J. Virol. 71:1997;7207-7213.
60. Overton H.A., et al. The protease and gag gene products of the human immunodeficiency virus: authentic cleavage and post-translational modification in an insect cell expression system. Virology. 170:1989;107-116.
61. Rasmussen L., et al. Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus. Virology. 178:1990;435-451.
62. Morikawa S., et al. Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors. Virology. 183:1991;288-297.
63. Thomsen D.R., et al. Expression of feline leukaemia virus gp85 and gag proteins and assembly into virus-like particles using the baculovirus expression vector system. J. Gen. Virol. 73:1992;1819-1824.
64. Rafnar B., et al. Immune response to recombinant visna virus Gag and Env precursor proteins synthesized in insect cells. Virus Res. 53:1998;107-120.
65. Kakker N., et al. Bovine leukemia virus Gag particle assembly in insect cells: formation of chimeric particles by domain-switched leukemia/lentitivirus Gag polyprotein. Virology. 2:1999;303-318.
66. Johnson M.C., et al. PR domain of rous sarcoma virus Gag causes an assembly/budding defect in insect cells. J. Virol. 75:2001;4407-4412.
67. Nagy E., et al. Synthesis of Newcastle disease virus (NDV)-like envelopes in insect cells infected with a recombinant baculovirus expressing the haemagglutinin-neuraminidase of NDV. J. Gen. Virol. 72:1991;753-756.
68. Fernandez-Arias A., et al. Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles. J. Gen. Virol. 79:1998;1047-1054.
69. Crawford S.E., et al. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J. Virol. 68:1994;5945-5952.
70. Brown C.S., et al. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins. J. Virol. 65:1991;2702-2706.
71. Christensen J., et al. Production of mink enteritis parvovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parvovirus in mink. J. Gen. Virol. 75:1994;149-155.
72. Hoque M., et al. Chimeric virus-like particle formation of adeno-associated virus. Biochem. Biophys. Res. Commun. 266:1999;371-376.
73. Noteborn M.H., et al. Simultaneous expression of recombinant baculovirus-encoded chicken anaemia virus (CAV) proteins VP1 and VP2 is required for formation of the CAV-specific neutralizing epitope. J. Gen. Virol. 79:1998;3073-3077.
74. Nawagitgul P., et al. Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein. J. Gen. Virol. 81:2000;2281-2287.
75. Kirnbauer R., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:1993;6929-6936.
76. Kosukegawa A., et al. Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. Biochim. Biophys. Acta. 1290:1996;37-45.
77. Chang D., et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J. Gen. Virol. 78:1997;1435-1439.
78. Kunke D., et al. Vaccinia virus recombinants co-expressing hepatitis B virus surface and core antigens. Virology. 195:1993;132-139.